Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
Authors
Keywords
Type 2 diabetes mellitus, Dipeptidyl peptidase-4 inhibitors, Cardiovascular diseases, Antidiabetic drugs, Hypoglycemia
Journal
Cardiovascular Diabetology
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-01
DOI
10.1186/s12933-016-0350-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus
- (2015) Shuo-Ming Ou et al. ANNALS OF INTERNAL MEDICINE
- The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death
- (2015) Oriana Hoi Yun Yu et al. Canadian Journal of Diabetes
- Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
- (2015) Enrique Z. Fisman et al. Cardiovascular Diabetology
- Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
- (2015) Y.-C. Chang et al. DIABETIC MEDICINE
- Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database
- (2015) Gian Paolo Fadini et al. EUROPEAN HEART JOURNAL
- Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
- (2015) Yuhao Huang et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database
- (2015) Cheng-Yang Hsieh et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients
- (2015) Dong-Yi Chen et al. MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan
- (2015) Szu-Heng Wang et al. PLoS One
- Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
- (2015) Jong-Mi Seong et al. PLoS One
- Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
- (2014) Seoyoung C. Kim et al. ACTA DIABETOLOGICA
- Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report
- (2014) Ikuko Nakamura et al. Cardiovascular Diabetology
- Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies
- (2014) Shang-Hung Chang et al. Cardiovascular Diabetology
- On the potential of acarbose to reduce cardiovascular disease
- (2014) Eberhard Standl et al. Cardiovascular Diabetology
- Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality
- (2014) C. Ll. Morgan et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study
- (2014) U. M. Mogensen et al. DIABETES OBESITY & METABOLISM
- Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan's National Health Insurance Research Database
- (2014) Hung-Lin Chen et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan
- (2014) Ching-Lan Cheng et al. JOURNAL OF EPIDEMIOLOGY
- Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study
- (2013) Chien-Jung Lu et al. CEREBROVASCULAR DISEASES
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
- (2013) D. T. Eurich et al. BMJ-British Medical Journal
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus
- (2011) Kristian B. Filion et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data
- (2011) Arlene M. Gallagher et al. PLoS One
- A web server for predicting inhibitors against bacterial target GlmU protein
- (2011) Deepak Singla et al. BMC Pharmacology & Toxicology
- Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study
- (2010) Casper H Jørgensen et al. Cardiovascular Diabetology
- Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
- (2010) Toru Kato et al. Cardiovascular Diabetology
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature
- (2009) L. Nalysnyk et al. DIABETES OBESITY & METABOLISM
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Association between serious ischemic cardiac outcomes and medications used to treat diabetes
- (2008) David J. Margolis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started